UroGen Pharma Ltd.
URGN
$18.44
-$0.35-1.86%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -20.98% | -42.70% | -36.43% | -32.70% | -24.09% |
| Total Depreciation and Amortization | 103.29% | 56.29% | 14.59% | -17.83% | -30.44% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -31.00% | -3.67% | -5.16% | 16.95% | 15.18% |
| Change in Net Operating Assets | -665.86% | 254.79% | 98.14% | 1,127.42% | 47.87% |
| Cash from Operations | -67.87% | -43.26% | -43.55% | -30.07% | -26.70% |
| Capital Expenditure | 2.03% | -63.98% | -65.00% | -98.25% | -52.06% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 404.40% | 202.71% | -392.24% | -1,024.14% | -2,576.94% |
| Cash from Investing | 398.64% | 202.04% | -399.77% | -1,054.63% | -2,062.96% |
| Total Debt Issued | -- | -100.00% | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -72.43% | -94.28% | -92.38% | -20.74% | 122.03% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -100.00% | -99.98% | -100.00% | -61.72% | -61.72% |
| Cash from Financing | -79.49% | -95.54% | -85.24% | -18.09% | 66.44% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -178.93% | -689.79% | -163.45% | -128.61% | 95.04% |